| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -620 | -910 | -530 | -170 | -250 |
| Net Income Growth | +31.87% | -71.70% | -211.76% | +32.00% | +3.85% |
Preveceutical Med Inc New
(PRVCF)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
PreveCeutical Medical Inc. is a health sciences company which develops preventive therapies utilizing organic and nature identical products. The company's research and development programs includes dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical (TM) peptides for treatment of ailments; non-addictive analgesic peptides, fentanyl and oxycodone and a therapeutic product for treating athletes who suffer from concussions. It sells CELLB9(R), an Immune System Booster. CELLB9(R) is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. PreveCeutical Medical Inc. is based in Vancouver, Canada.
Fiscal Year End Date: 12/31